Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin Gel 3% pharmacokinetic dose-ranging study in healthy volunteers
2005-002157-51Phase 2Completed
- Sponsor
- Antares Pharma, Inc.
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxybutynin in overactive bladder (OAB) (3 arms), sponsored by Antares Pharma, Inc. Primary endpoints: Single-dose and multiple-dose pharmacokinetics of topical oxybutynin gel 3%, Safety and tolerability and 1 more. Started Jun 2005; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-002157-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002157-51.